Ultragenyx Faces Class Action Allegations Over Setrusumab Trial Misleading Statements
- A class action lawsuit against Ultragenyx concerns alleged misleading information about setrusumab's trial results for Osteogenesis Imperfecta.
- Investors in Ultragenyx's common stock from August 2023 to December 2025 may be eligible to participate in the lawsuit.
- The lawsuit's outcome could impact Ultragenyx's reputation and investor trust in its clinical trial processes and corporate communications.
Ultragenyx Faces Class Action Over Setrusumab Trials
The development of Ultragenyx Pharmaceutical Inc.'s treatment setrusumab (UX 143) for Osteogenesis Imperfecta (OI) has come under scrutiny as a class action lawsuit looms. Rosen Law Firm, a leading entity in investor rights, reminds shareholders who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, about the impending lead plaintiff deadline of April 6, 2026. This legal action arises from allegations that Ultragenyx misled investors concerning the trial results of the Phase III Orbit and Cosmic Studies, which aim to demonstrate setrusumab's effectiveness in reducing fracture rates among OI patients.
The lawsuit claims that executives and representatives of Ultragenyx provided overly optimistic projections about setrusumab’s therapeutic effects, failing to reveal critical information that might contradict these positive assertions. Investors participating in the class action may potentially receive compensation without incurring any out-of-pocket expenses, as the firm operates on a contingency fee basis. Shares acquired within the specified timeframe could render these investors eligible to join the case, prompting them to either visit the Rosen Law Firm website or directly engage with attorney Phillip Kim for more information on participating as lead plaintiffs.
Rosen Law Firm is well-regarded in the legal domain for its successful track record in managing securities class actions. The firm has previously garnered significant settlements for aggrieved investors, including over $438 million in 2019 alone. In addition, the firm maintains its reputation as a leader in the field, ranking number one for the quantity of securities class action settlements in 2017, a title it has sustained since. As the April 2026 deadline approaches, potential plaintiffs must act promptly to ensure their representation in this pivotal lawsuit.
Ultragenyx, primarily focused on creating novel therapies for rare genetic diseases, must navigate the implications of this class action, which not only seeks to address investor grievances but also magnifies the scrutiny on its clinical trial processes and corporate communications. The outcome may influence both investor perceptions and the company's reputation in an industry where trust is paramount.
